Breast

High Levels Of Fertility-Related Hormone Linked To Increased Breast Cancer Risk, New Study Finds

(ICR [UK]) Sept 17, 2018 - Having high levels of anti-Müllerian hormone (AMH) – a hormone that indicates the size of a woman’s ovarian reserve – before the menopause is associated with an increased risk of breast cancer, research suggests. In a major study, leading scientists from the NYU School of Medicine analysed blood samples from participants of ten cohort studies – including the Breast Cancer Now Generations Study at The Institute of Cancer Research, London – to examine the association of AMH levels with breast cancer risk. The team examined blood samples from 5,957 premenopausal women from across the USA, the UK, Sweden and Italy, and found that those in the quartile with the highest levels of AMH in their blood were 60% more likely to develop breast cancer – both before and after menopause – when compared to those in the lowest quartile.

read article

Mental Health May Predict Pain Levels After Breast Cancer Treatment

(University of Michigan/Michigan Health) Sept 18, 2018 - About a quarter of women treated for breast cancer experience moderate to severe pain for many years after their treatment ends. Sometimes, there’s no obvious reason why.

read article

You Might Want Artificial Intelligence Reading Your Next Mammogram

(Forbes) Sept 18, 2018 - What many women may not know is that breast screening programs produce a high level of false positive results, particularly after multiple years of screening. In other words, women are informed they may have cancer when in fact they don’t.

read article

Statement from Binita Ashar, M.D., of the FDA’s Center for Devices and Radiological Health on Agency’s Commitment To Studying Breast Implant Safety

(FDA.gov) Sept 14, 2018 - Choosing to obtain a breast implant, whether for augmentation or reconstruction, is a deeply personal choice, from the initial decision to undergo breast implant surgery to the size, material and surface texture. These types of decisions should be discussed between a patient and their provider in a transparent and balanced way with clear information about the benefits and risks of the breast implants and the procedure. As a public health agency, we play an important role in ensuring that patients seeking breast augmentation and breast reconstruction have accurate information regarding the benefits and risks of breast implants to make informed decisions on whether implants may be right for them.

read press release

New Approach to Breast Reconstruction May Reduce Pain and Weakness for Some

(New York Times) Sept 17, 2018 - Before Deborah Cohan had a double mastectomy and breast reconstruction five years ago, her plastic surgeon explained that he would “create a little pocket” behind her chest muscle and “slip the implant in.” Her doctor glossed over the part of the procedure in which the large pectoralis major muscles are detached from some underlying ribs, pulled off the chest wall, then stretched out for several months to accommodate breast implants. The process can weaken the muscle and left Dr. Cohan, an obstetrician, with chronic pain that made it difficult for her to work at a computer, let alone deliver babies.

read article

Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522

(NASDAQ) Sept 17, 2018 - Phase 1 clinical trial to resume enrollment of new patients.

read article

FDA Plans Meeting to Discuss Safety Data on Breast Implants

(ABC News/Associated Press) Sept 14, 2018 - U.S. health regulators say they'll convene a public meeting of medical advisers next year to discuss new science on breast implant safety, including an independent analysis that suggests certain rare health problems might be more common with silicone gel implants. The Food and Drug Administration said it would hold the meeting even as its officials and several independent experts disputed the new work. Leaders of the study concede that it has big limitations and cannot prove that implants cause any of these problems. Yet it involves nearly 100,000 women and is the largest long-term safety analysis of silicone implants since 2006, when they were allowed back on the U.S. market after a 14-year gap due to safety concerns.

read article

Majority of Women Receive Breast Cancer Diagnosis Over The Phone

(MU School of Medicine) Sept 11, 2018 - A new study from the University of Missouri School of Medicine reveals an increasing number of women are learning about their breast cancer diagnosis over the phone. It's a finding that has prompted the MU School of Medicine to develop new training methods to better prepare future physicians to deliver negative news without being face-to-face with patients.

read article

Huge Genetic-Screening Effort Helps Pinpoint Roots Of Breast Cancer

(Nature.com) Sept 12, 2018 - A massive study of nearly 4,000 variants in a gene associated with cancer could help to pinpoint people at risk for breast or ovarian tumours. The information is sorely needed: millions of people have had their BRCA1 gene sequenced. Some variations in the DNA sequence of BRCA1 are linked to breast and ovarian cancer; others are thought to be safe. But the effects of most variants are unknown, leaving patients and physicians alike at a loss to interpret the results. The study, published on 12 September in Nature, examined the effects of thousands of such variants on the survival of cells grown in the laboratory.

read article

What's Your Breast Cancer Risk? This Study Aims To Tell You Precisely

(NBCNews.com) Sept 12, 2018 - Breast cancer is one of the most worrisome diagnoses a woman can get, and now women know that they can get a heads-up if they have an extra-high risk by getting a genetic test. Mutations in dozens of different genes can raise the risk of breast cancer, but the two best-known risk genes are BRCA1 and BRCA2. Everyone carries these genes. When breast cancer, ovarian cancer or prostate cancer runs in a family, doctors often advise getting a test to assess whether a patient carries a risky version of one of them. Now there are home tests for common BRCA1 and BRCA2 mutations. Some clearly raise a woman's risk of cancer, and she can get more regular mammograms or, as actress Angelie Jolie opted to do, have her breasts surgically removed.

read article

Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen

(Morningstar) Sept 13, 2018 - Atossa Genetics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported preliminary results from its Phase 1 dose-escalation study of its proprietary topical Endoxifen in male subjects.

read article

Prominent Health Policy Researcher Resigns From Dartmouth Over Plagiarism Dispute

(STAT) Sept 13, 2018 - Dr. H. Gilbert Welch, one of the country’s top health care policy scholars, has resigned from his faculty position at Dartmouth College, after an investigation by the school concluded that he had committed research misconduct.

read article

I-SPY 2, an Innovative Clinical Trial Model that is Revolutionizing the Treatment of Early Stage, High-Risk Breast Cancer

(QLHC) Sept 12, 2018 - Presentation of advances from the groundbreaking I-SPY 2 TRIAL.

read press release

Oncternal Announces First Patient Dosed in Phase 1b Clinical Trial of Cirmtuzumab in Combination with Paclitaxel in Patients with Breast Cancer

(The Business Journals) Sept 12, 2018 - Oncternal Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies for rare and common malignancies, today announced the first patient has been dosed in a Phase 1b study of cirmtuzumab, an anti-ROR1 monoclonal antibody, in combination with standard-of-care chemotherapy drug paclitaxel in patients with HER2/neu negative metastatic or locally advanced, unresectable breast cancer.

read article

Study: Biosimilar Filgrastim Associated With Fewer Adverse Events than Biosimilar Pegfilgrastim

(The Center of Biosimilars) Sept 10, 2018 - A study compared 24 patients’ grade of neutropenia and AEs after receiving biosimilar filgrastim (Zarxio) and biosimilar pegfilgrastim (Pegagen).

read article

Study Finds No Difference In Disease-Free, Overall Survival For HER2+ Breast Cancer Patients Receiving Treatment Concurrently Or Sequentially

(MD Anderson) Sept 6, 2018 - New research in women with HER2+ breast cancer found no difference in disease-free survival (DFS) and overall survival (OS) when receiving anthracycline-based chemotherapy and trastuzumab concurrently or sequentially in the neoadjuvant setting. Findings from The University of Texas MD Anderson Cancer Center-led study published today in JAMA Oncology.

read press release

Scientists Develop New Way To Identify Breast Cancer Tumors

(USC News) Sept 6, 2018 - Potentially lifesaving breakthrough for women devised by USC-led research team takes big step forward from biopsies and microscopes.

read article

Biomarker Tests In Breast Cancer: New Study Data Indicate Advantage For Certain Patients

(IQWiG [Germany]) Sept 5, 2018 - The German Institute for Quality and Efficiency in Health Care (IQWiG) reinvestigated the benefit of biomarker tests to support the decision for or against adjuvant systemic chemotherapy in certain breast cancer patients, that is, women with primary hormone receptor-positive, HER2/neu-negative breast cancer and 0 to 3 affected lymph nodes.

read press release

Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab‎ For The I-SPY 2 Trial For Breast Cancer

(QLHC) Sept 6, 2018 - Quantum Leap Healthcare Collaborative™ (QLHC) announced today that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL™ includes the study of olaparib and durvalumab, two agents from AstraZeneca.

read press release

Athenex Announces Positive Recommendation by the Drug Safety Monitoring Board Upon the Second Interim Analysis and to Continue the Oraxol Phase III Program

(MarketWatch) Sept 5, 2018 - Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the planned second interim analysis of the Oraxol 001 Phase III Clinical Trial in metastatic breast cancer has been conducted and reviewed by an independent Drug Safety Monitoring Board (DSMB).

read article
Next Page